Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 16/20 | 0.69 |
| ▸ | JAK2 | O60674 | 2/20 | 0.59 |
| ▸ | JAK3 | P52333 | 1/20 | 0.59 |
| ▸ | IGF1R | P08069 | 3/20 | 0.52 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | HTR7 | P34969 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22535379 | 0.93 | NTRK1 (0.61) | NTRK1JAK2JAK3IGF1RADRA1D | |
| SCHEMBL22535847 | 0.91 | NTRK1 (0.70) | NTRK1JAK2JAK3IGF1R | |
| SCHEMBL22535694 | 0.91 | NTRK1 (0.70) | NTRK1JAK2JAK3IGF1R | |
| SCHEMBL22535613 | 0.91 | NTRK1 (0.56) | NTRK1JAK2JAK3IGF1R | |
| SCHEMBL22535330 | 0.90 | NTRK1 (0.57) | NTRK1JAK2JAK3IGF1R | |
| SCHEMBL22535356 | 0.90 | NTRK1 (0.56) | NTRK1JAK2JAK3IGF1R | |
| SCHEMBL22535724 | 0.88 | NTRK1 (0.67) | NTRK1JAK2JAK3IGF1R | |
| SCHEMBL22535533 | 0.87 | NTRK1 (0.54) | NTRK1JAK2JAK3IGF1R | |
| SCHEMBL22535532 | 0.87 | NTRK1 (0.54) | NTRK1JAK2JAK3IGF1R | |
| SCHEMBL22535688 | 0.87 | NTRK1 (0.76) | NTRK1JAK2JAK3IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10800760-B2 | Trk inhibition | NANTBIO, INC. (US) | 2020-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10800760-B2 | Trk inhibition | NTRK1, NTRK3, NTRK2 | NTRK1 1/4885JAK2 833/4885JAK3 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.